Addison's Disease Market Threats in the Target Market and Forecast By 2023

Posted by vinit sawant on February 10th, 2021

According to a report published by the National Center for Biotechnology Information in June 2017, the incidence rate of Addison's disease is 0.6 per 100,000 of the population per year. Despite the drivers, difficulty in diagnosis in early stages and lack of knowledge can restrain the market growth over the assessment period.

The Global Addison's Disease Market is anticipated to hold a market value of USD 168 million in the year 2017 and is expected to grow at a CAGR of 10.4% during the forecast period. Addison's disease occurs when the body starts producing inadequate amounts of certain hormones produced by adrenal glands. The glands start to produce too less cortisol and aldosterone as well. Addison's disease is a rare disorder, and only 1 in 100,000 people suffer from it.

Segmentation

The global Addison's Disease Market has been segmented into diagnosis, treatment and end user.

The market, on the basis of diagnosis, has been segmented into laboratory testing and imaging tests. Laboratory testing is further segmented into blood tests, ACTH stimulation test, insulin-induced hypoglycemia test, and other tests. Imaging tests are further segmented into chest radiography and CT scan.

The global market, on the basis of treatment, has been segmented into oral corticosteroids and corticosteroid injections. Oral corticosteroids are expected to hold the largest share owing to high prefer ability of oral dosage forms like tablets.

Regional Analysis

Geographically, the Americas is expected to dominate the global market owing to the presence of well-developed healthcare sector, raising awareness of the disease and favorable reimbursement policies.